The influence of mifepristone to caspase 3 expression in adenomyosis
- PMID: 24779241
The influence of mifepristone to caspase 3 expression in adenomyosis
Abstract
Objective: To discuss the influence of mifepristone to caspase 3 expression in adenomyosis tissue.
Materials and methods: Sixty patients were equally divided into four groups. Groups 1, 2, and 3 were treated with 5, 10, and 15 mg mifepristone, respectively and group 4 was treated with placebo. The expression of caspase 3 was examined by immunohistochemical method in both eutopic and ectopic endometria of the 40 cases.
Results: Compared with placebo group, the expression of caspase 3 in both eutopic endometrium and ectopic endometrium in the three treatment groups was significantly increased. There was no difference in the expression of caspase 3 in both eutopic and ectopic endometria between the ten and 25 mg treatment groups, while both the ten and 25 mg treatment groups had a higher expression intensity of caspase 3 in both eutopic and ectopic endometria, compared with the five mg treatment group (p < 0.01).
Conclusion: Mifepristone can increase the expression of caspase 3 in both eutopic and ectopic endometria and initiate cell apoptosis in both eutopic and ectopic endometria. Therefore mifepristone can effectively inhibit the emergence and development of adenomyosis.
Similar articles
-
Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis.Reprod Biol Endocrinol. 2021 Jul 21;19(1):114. doi: 10.1186/s12958-021-00800-6. Reprod Biol Endocrinol. 2021. PMID: 34289871 Free PMC article.
-
Increased expression of Talin1 in the eutopic and ectopic endometria of women with adenomyosis.Gynecol Endocrinol. 2016 Jun;32(6):469-72. doi: 10.3109/09513590.2015.1130811. Epub 2016 Jan 13. Gynecol Endocrinol. 2016. PMID: 26759065
-
Decreased expression of interleukin-37 in the ectopic and eutopic endometria of patients with adenomyosis.Gynecol Endocrinol. 2018 Jan;34(1):83-86. doi: 10.1080/09513590.2017.1354367. Epub 2017 Aug 1. Gynecol Endocrinol. 2018. PMID: 28762845
-
Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review.Hum Reprod Update. 2019 Sep 11;25(5):647-671. doi: 10.1093/humupd/dmz024. Hum Reprod Update. 2019. PMID: 31504506 Free PMC article.
-
The endometrium in adenomyosis.Womens Health (Lond). 2012 May;8(3):301-12. doi: 10.2217/whe.12.8. Womens Health (Lond). 2012. PMID: 22554177 Review.
Cited by
-
Current Medical Therapy for Adenomyosis: From Bench to Bedside.Drugs. 2023 Nov;83(17):1595-1611. doi: 10.1007/s40265-023-01957-7. Epub 2023 Oct 14. Drugs. 2023. PMID: 37837497 Free PMC article. Review.
-
Adenomyosis: An Update Concerning Diagnosis, Treatment, and Fertility.J Clin Med. 2024 Sep 3;13(17):5224. doi: 10.3390/jcm13175224. J Clin Med. 2024. PMID: 39274438 Free PMC article. Review.
-
Changes in surface morphology, lectin staining, and gene expression of caprine endometrium exposed to estradiol, progesterone, and mifepristone in vitro.Iran J Vet Res. 2022;23(1):61-68. doi: 10.22099/IJVR.2021.41508.6036. Iran J Vet Res. 2022. PMID: 35782354 Free PMC article.
-
The Present and the Future of Medical Therapies for Adenomyosis: A Narrative Review.J Clin Med. 2023 Sep 22;12(19):6130. doi: 10.3390/jcm12196130. J Clin Med. 2023. PMID: 37834773 Free PMC article. Review.
-
Clinical Utility of Mifepristone: Apprising the Expanding Horizons.Cureus. 2022 Aug 23;14(8):e28318. doi: 10.7759/cureus.28318. eCollection 2022 Aug. Cureus. 2022. PMID: 36158399 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials